Autres langues IntelGenx Technologies Corp.

Actions

IGXT

US45822R1014

Marché Fermé - OTC Markets Autres places de cotation 21:57:51 06/05/2024			Varia. 5j.	Varia. 1 janv.
0,19 ^USD	+6,15%		+18,75%	+37,58%

08/04	Intelgenx annonce que les premiers patients atteints de la maladie de Parkinson ont reçu le Montelukast Versafilm® dans le cadre de l'essai clinique de phase 2 " Montpark ". Montpark ?	CI
05/04	IntelGenx met à jour le statut de la Buprenorphine Buccal Film ANDA	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial	08/04
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	08/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	08/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	05/04
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	21/03
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results	21/03
IntelGenx Technologies : 25 10.42pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03
IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow	14/03
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding	08/03
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering	20/02
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million	20/02
IntelGenx Technologies Corp. announced that it expects to receive $20 million in funding	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues IntelGenx Technologies Corp.

Actions

IGXT

US45822R1014

Autres langues

Filtres